COMPANY

Acepodia

Keywords: cell therapy antibody-drug conjugate ADC antibody oncology hematology cancer solid tumor Hepatocellular Carcinoma Hepatocellular Carcinoma Metastatic Hepatocellular Carcinoma Non-Resectable IgG4 Related Disease B-cell Lymphoma Non Hodgkin Lymphoma DLBCL Primary Mediastinal Large B Cell Lymphoma Marginal Zone Lymphoma Follicular Lymphoma Burkitt Lymphoma High-grade B-cell Lymphoma HER2-positive Gastric Cancer HER2-positive Metastatic Breast Cancer ACE1831 ACE723 ACE2016 ACE1702

Location: Alameda, CA · source · Oct 15, 2026

Profile checked Oct 10, 2026

5Trials (company is sponsor)

Timeline

2026-11 Trial start 1: Phase 1 Trial of ACE723, A Dual-Payload Antibody Drug Conjugate, in Patients With Advanced HCC Who Have Failed or Progressed on Standard Systemic Therapy Containing ICIs source ↗
Jan 1, 2026 Trial start Phase 1/Phase 2: Study to Assess Safety, Efficacy and Persistence of ACE1831, in Subjects With IgG4-Related Disease source ↗
Aug 22, 2024 Trial start Phase 1: ACE2016 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors Expressing Epidermal Growth Factor Receptor (EGFR) source ↗
Jan 21, 2023 Trial start Phase 1: ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies source ↗
Jun 24, 2020 Trial start Phase 1: ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors source ↗

Upcoming milestones

Dec 31, 2026 (ESTIMATED) · Phase 1 · ACE2016 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors Expressing Epidermal Growth Factor Receptor (EGFR) · NCT06415487
Sep 20, 2029 (ESTIMATED) · Phase 1/Phase 2 · Study to Assess Safety, Efficacy and Persistence of ACE1831, in Subjects With IgG4-Related Disease · NCT07061938
2030-05 (ESTIMATED) · 1 · Phase 1 Trial of ACE723, A Dual-Payload Antibody Drug Conjugate, in Patients With Advanced HCC Who Have Failed or Progressed on Standard Systemic Therapy Containing ICIs · NCT07861425

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 5

Record	Title	Phase	Status	Start	Primary completion
NCT07861425	Phase 1 Trial of ACE723, A Dual-Payload Antibody Drug Conjugate, in Patients With Advanced HCC Who Have Failed or Progressed on Standard Systemic Therapy Containing ICIs	1	Not yet recruiting	2026-11	2030-05 (estimated)
NCT07061938	Study to Assess Safety, Efficacy and Persistence of ACE1831, in Subjects With IgG4-Related Disease	Phase 1/Phase 2	Recruiting	Jan 1, 2026	Sep 20, 2029 (estimated)
NCT05653271	ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies	Phase 1	Completed	Jan 21, 2023	Mar 31, 2026 (actual)
NCT06415487	ACE2016 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors Expressing Epidermal Growth Factor Receptor (EGFR)	Phase 1	Recruiting	Aug 22, 2024	Dec 31, 2026 (estimated)
NCT04319757	ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors	Phase 1	Completed	Jun 24, 2020	Jul 15, 2024 (actual)